102 related articles for article (PubMed ID: 3991530)
1. Red blood cells indices and aluminium toxicity in haemodialysis patients.
Tielemans C; Kalima L; Collart F; Wens R; Smeyers-Verbeke J; Verbeelen D; Dratwa M
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():395-8. PubMed ID: 3991530
[TBL] [Abstract][Full Text] [Related]
2. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication.
Short AI; Winney RJ; Robson JS
Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773
[TBL] [Abstract][Full Text] [Related]
3. Bone scan in haemodialysis patients: relation to hyperparathyroidism and aluminium toxicity.
Tielemans C; Wens R; Collart F; Dratwa M; Smeyers-Verbeke J; Van Hooff I; De Roy G; Bergmann P; Verbeelen D
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():399-402. PubMed ID: 3991531
[TBL] [Abstract][Full Text] [Related]
4. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
Altmann P; Plowman D; Marsh F; Cunningham J
Lancet; 1988 May; 1(8593):1012-5. PubMed ID: 2896867
[TBL] [Abstract][Full Text] [Related]
5. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
7. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine.
de la Serna FJ; Praga M; Gilsanz F; Rodicio JL; Ruilope LM; Alcazar JM
Lancet; 1988 May; 1(8593):1009-11. PubMed ID: 2896866
[TBL] [Abstract][Full Text] [Related]
9. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
[TBL] [Abstract][Full Text] [Related]
10. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies.
Touam M; Martinez F; Lacour B; Bourdon R; Zingraff J; Di Giulio S; Drüeke T
Clin Nephrol; 1983 Jun; 19(6):295-8. PubMed ID: 6872366
[TBL] [Abstract][Full Text] [Related]
11. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin, aluminium, and anaemia in patients on haemodialysis.
Rosenlöf K; Fyhrquist F; Tenhunen R
Lancet; 1990 Feb; 335(8684):247-9. PubMed ID: 1967718
[TBL] [Abstract][Full Text] [Related]
13. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
[TBL] [Abstract][Full Text] [Related]
14. Aluminium load in patients with analgesic nephropathy.
Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G
Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045
[TBL] [Abstract][Full Text] [Related]
15. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
Abreo K; Brown ST; Sella M; Trapp G
J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
[TBL] [Abstract][Full Text] [Related]
16. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
[TBL] [Abstract][Full Text] [Related]
17. Aluminium-induced anaemia in haemodialysis patients.
McGonigle RJ; Parsons V
Nephron; 1985; 39(1):1-9. PubMed ID: 3969184
[TBL] [Abstract][Full Text] [Related]
18. Hypochromic anaemia in chronic renal failure--role of aluminium.
Varma PP; Kumar R; Prasher PK; Roy ND
J Assoc Physicians India; 1999 Jul; 47(7):690-3. PubMed ID: 10778588
[TBL] [Abstract][Full Text] [Related]
19. Iron induced increase in red cell size in haemodialysis patients.
Gokal R; Weatherall DJ; Bunch C
Q J Med; 1979 Jul; 48(191):393-401. PubMed ID: 542585
[TBL] [Abstract][Full Text] [Related]
20. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity.
Altmann P; Dhanesha U; Hamon C; Cunningham J; Blair J; Marsh F
Lancet; 1989 Jul; 2(8653):7-12. PubMed ID: 2567838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
